Modifying CV risk by managing diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Disease-modifying effects of finerenone in CKM syndrome
Disease-modifying effects of finerenone in CKM syndrome
ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
- Muthiah Vaduganathan, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Pam R. Taub, MD, FACC, FASPC